Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Effects of Sheng-Mai Injection on Diabetes Mellitus: A Systematic Review and Meta-analysis

Author(s): Maoyi Yang, Zhipeng Hu* and Rensong Yue

Volume 23, Issue 8, 2023

Published on: 21 March, 2023

Page: [1051 - 1067] Pages: 17

DOI: 10.2174/1871530323666230127121738

Price: $65

conference banner
Abstract

Background: Diabetes mellitus (DM) is a metabolic disorder characterized by progressive β cell dysfunction. Sheng-Mai Injection (SMI), a Traditional Chinese medicine preparation, is widely used for DM and its related complications.

Objective: This meta-analysis aimed to summarize the applications of SMI in DM and related complications.

Methods: Eight databases were searched, and meta-analyses were performed.

Results: Fifteen studies, including 1273 participants, were included. All studies and participants included were from China. Pooled effects showed that SMI might reduce glycated hemoglobin (MD -0.46%; 95% CI -0.89 to -0.03; P < 0.01), fasting blood glucose (MD -0.83 mmol/L; 95% CI -1.30 to -0.36; P < 0.01), two-hour postprandial glucose (MD -1.27 mmol/L; 95% CI -1.96 to -0.58; P < 0.01), 24-hour urinary protein (MD -0.28 mg; 95% CI -0.51 to -0.06; P = 0.01), blood urea nitrogen (MD -1.31 mg; 95% CI -2.08 to -0.54; P < 0.05), Scr (MD -2.60; 95% CI -3.43 to -1.77; P < 0.05), ulnar nerve motor nerve conduction velocity (MNCV) (MD 1.45; 95% CI 0.03 to 2.87; P < 0.05), and tibial nerve sensory nerve conduction velocity (SNCV) (MD 1.84; 95% CI 0.1 to 3.58; P < 0.05). There was no evidence of an effect on common peroneal nervous MNCV and SNCV, tibial nerve MNCV, median nerve MNCV, and SNCV. Adverse effects included less frequent gastrointestinal reactions, elevated transaminase, leucopenia, fever, and rash.

Conclusion: Combination use of SMI based on conventional hypoglycemic treatment can significantly improve HbA1c, FBG, and 2hPG in DM and reduce 24-hour urinary protein, Scr, and BUN in DM patients. SMI was found to have no effect on the neurological function of diabetic peripheral neuropathy.

« Previous Next »
Graphical Abstract

[1]
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2021, 44(S1), S15-S33.
[http://dx.doi.org/10.2337/dc21-S002] [PMID: 33298413]
[2]
Cho, N.H.; Shaw, J.E.; Karuranga, S.; Huang, Y.; da Rocha Fernandes, J.D.; Ohlrogge, A.W.; Malanda, B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract., 2018, 138, 271-281.
[http://dx.doi.org/10.1016/j.diabres.2018.02.023] [PMID: 29496507]
[3]
Li, Y.; Teng, D.; Shi, X.; Qin, G.; Qin, Y.; Quan, H.; Shi, B.; Sun, H.; Ba, J.; Chen, B.; Du, J.; He, L.; Lai, X.; Li, Y.; Chi, H.; Liao, E.; Liu, C.; Liu, L.; Tang, X.; Tong, N.; Wang, G.; Zhang, J.; Wang, Y.; Xue, Y.; Yan, L.; Yang, J.; Yang, L.; Yao, Y.; Ye, Z.; Zhang, Q.; Zhang, L.; Zhu, J.; Zhu, M.; Ning, G.; Mu, Y.; Zhao, J.; Teng, W.; Shan, Z. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020, 369, m997.
[http://dx.doi.org/10.1136/bmj.m997] [PMID: 32345662]
[4]
Reed, J.; Bain, S.; Kanamarlapudi, V. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes Metab. Syndr. Obes., 2021, 14, 3567-3602.
[http://dx.doi.org/10.2147/DMSO.S319895] [PMID: 34413662]
[5]
Tinajero, M.G.; Malik, V.S. An update on the epidemiology of type 2 diabetes. Endocrinol. Metab. Clin. North Am., 2021, 50(3), 337-355.
[http://dx.doi.org/10.1016/j.ecl.2021.05.013] [PMID: 34399949]
[6]
Association, A.D. Economic costs of diabetes in the U.S. in 2017. Diabetes Care, 2018, 41(5), 917-928.
[http://dx.doi.org/10.2337/dci18-0007] [PMID: 29567642]
[7]
Dall, T.M.; Yang, W.; Gillespie, K.; Mocarski, M.; Byrne, E.; Cintina, I.; Beronja, K.; Semilla, A.P.; Iacobucci, W.; Hogan, P.F. The economic burden of elevated blood glucose levels in 2017: Diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care, 2019, 42(9), 1661-1668.
[http://dx.doi.org/10.2337/dc18-1226] [PMID: 30940641]
[8]
Saeedi, P.; Salpea, P.; Karuranga, S.; Petersohn, I.; Malanda, B.; Gregg, E.W.; Unwin, N.; Wild, S.H.; Williams, R. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract., 2020, 162, 108086.
[http://dx.doi.org/10.1016/j.diabres.2020.108086] [PMID: 32068099]
[9]
Yun, J.S.; Ko, S.H. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism, 2021, 123154838
[http://dx.doi.org/10.1016/j.metabol.2021.154838] [PMID: 34333002]
[10]
Hu, Z.; Liu, X.; Yang, M. Evidence and potential mechanisms of Jin-Gui Shen-Qi Wan as a treatment for type 2 diabetes mellitus: A systematic review and meta-analysis. Front. Pharmacol., 2021, 12699932
[http://dx.doi.org/10.3389/fphar.2021.699932] [PMID: 34552482]
[11]
Chen, C.Y.; Lu, L.Y.; Chen, P.; Ji, K.T.; Lin, J.F.; Yang, P.L. Shengmai injection, a traditional chinese patent medicine, for intradialytic hypotension: a systematic review and meta-analysis. Evid.-based Complement. Altern. Med., 2013, 2013703815
[http://dx.doi.org/10.1155/2013/703815]
[12]
Duan, B.; Xie, J.; Rui, Q.; Zhang, W.; Xi, Z. Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis. Supportive Care in Cancer, 2018, 26(7), 2103-11.
[http://dx.doi.org/10.1007/s00520-018-4167-4]
[13]
Huang, X.; Duan, X.; Wang, K.; Wu, J.; Zhang, X. Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Complement. Ther. Med., 2019, 43, 140-147.
[http://dx.doi.org/10.1016/j.ctim.2019.01.020] [PMID: 30935521]
[14]
Li, T-q.; Liu, X-m.; Feng, M. Systematic review on the application and adverse reactions of shengmai injection. Chinese J. Integrat. Tradit. Western Med., 2009, 29(11), 965-9.
[15]
Wang, Y.; Zhou, X.; Chen, X.; Wang, F.; Zhu, W.; Yan, D. Efficacy and safety of shengmai injection for chronic heart failure: a systematic review of randomized controlled trials. Evid.-. Based Complement. Altern. Med., 2020, 20209571627
[http://dx.doi.org/10.1155/2020/9571627]
[16]
Cao, Y.; Han, X.; Pan, H.; Jiang, Y.; Peng, X.; Xiao, W. Emerging protective roles of shengmai injection in septic cardiomyopathy in mice by inducing myocardial mitochondrial autophagy via caspase-3/Beclin-1 axis. Inflamm. Res., 2020, 69(1), 41-50.
[17]
Chen, Q.; Zhang, P.; Xiao, Q-X.; Liu, Q.; Zhang, Y. Protective effect of Shengmai injection on myocardial endothelial cell glycoprotein detachment after myocardial ischemia-reperfusion injury in isolated rat hearts. Perfusion, 2020.267659120965921
[PMID: 33070762]
[18]
Zhan, S.; Shao, Q.; Fan, X.; Li, Z. Development of a sensitive LC-MS/MS method for simultaneous quantification of eleven constituents in rat serum and its application to a pharmacokinetic study of a Chinese medicine Shengmai injection. Biomed. Chromatogr., 2015, 29(2), 275-284.
[http://dx.doi.org/10.1002/bmc.3273] [PMID: 25043947]
[19]
Li, F.; Cheng, T.; Dong, X.; Li, P.; Yang, H. Global analysis of chemical constituents in Shengmai injection using high performance liquid chromatography coupled with tandem mass spectrometry. J. Pharm. Biomed. Anal., 2016, 117, 61-72.
[http://dx.doi.org/10.1016/j.jpba.2015.08.022] [PMID: 26342447]
[20]
Clinical observation on shengmai injection in prevention and treatment of 45 cases of diabetes complicated with coronary heart disease. Hui, Z.; Gang, Z.; Qing, H., Eds.; The Sixth Academic Conference of the National Cardiovascular Association of Integrated Traditional Chinese and Western Medicine, Beijing, China2002.
[21]
Fuqin, W.; Hui, X.; Zheng, L.; Chengwei, L.; Xinghua, J.; Li, C. Clinical observation of Shengmai injection combined with puerarin in the treatment of type 2 diabetes with acute non ST segment elevation myocardial infarction. TCM Emergency, 2017, 26(05), 924-6.
[22]
Lijun, L. Clinical observation on 108 cases of diabetes complicated with coronary heart disease treated with Shengmai injection. Chinese Med. Clin., 2010, 10(10), 1157-8.
[23]
Zhaohui, J.; Liuxiang, H. Shengmai injection in the treatment of 22 cases of type 2 diabetes complicated with coronary heart disease. Hunan J. Tradit. Chinese Med., 2004, 03(17), 8-47.
[24]
Jiqing, L. Clinical observation on 38 cases of diabetes cerebral infarction treated by point injection of shengmai injection. Heilongjiang Tradit. Chinese Med., 2001, (6), 46-47.
[25]
Chang, L.; Li, M. Shengmai injection in treating 39 cases of arrhythmia in diabetes heart disease. Jiangxi Tradit. Chinese Med., 2002, (05), 19.
[26]
Xiaoqiu, W. Clinical Study of Shengmai Injection Based on Metabolomics in Intervention of Qi Yin Deficiency Syndrome of Type 2 diabetes Mellitus; Guangzhou University of Traditional Chinese Medicine, 2013.
[27]
Shunyuan, D.; Hanmao, J. Effect of Shengmai injection on blood TNF in patients with type 2 diabetes nephropathy- α, impact of IL-6. Zhongyuan Med. J., 2004, (14), 2-4.
[28]
Shunyuan, D.; Ming, Y.; Junfa, X.; Hanmao, J. Effect of shengmai injection on tumor necrosis factor in blood of type 2 diabetes nephropathy patients α and interleukin-6. Clin. Rehab. China, 2005, (03), 172-174.
[29]
Lijun, C.; Ning, W. Effect of shengmai injection on proliferation of mesangial cells induced by high glucose and advanced glycation end products. J. Nanjing Uni. Tradit. Chinese Med., 2010, 26(06), 445-446.
[30]
Bin, C; Suli, W; Jichun, S; Haiyan, G; Yue, D. Effects of Shengmai injection on renal function, MMP and TIMP in rabbits with diabetes ketoacidosis. TCM emergency, 2018, 27(11), 1922-6.
[31]
Xiusong, Y.; Xiuyu, Y. Effect of shengmai injection on microinflammatory state of diabetes nephropathy. Chinese J. Nephrop. Integ. Tradit. Chinese Western Med., 2011, 12(08), 733-734.
[32]
Yixuan, L. Preliminary Study on the Mechanism of Shengmai Injection in Preventing and Treating Sugar Kidney from the Perspective of Mitochondria endoplasmic reticulum Structural Coupling; Beijing University of Traditional Chinese Medicine, 2018.
[33]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372(71)
[34]
Page, M.J.C.M.; Chandler, J.; Lasserson, T. Chapter III Reporting the review. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2; Cochrane, 2021.
[35]
Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; Emberson, J.R.; Hernán, M.A.; Hopewell, S.; Hróbjartsson, A.; Junqueira, D.R.; Jüni, P.; Kirkham, J.J.; Lasserson, T.; Li, T.; McAleenan, A.; Reeves, B.C.; Shepperd, S.; Shrier, I.; Stewart, L.A.; Tilling, K.; White, I.R.; Whiting, P.F.; Higgins, J.P.T. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366, l4898.
[http://dx.doi.org/10.1136/bmj.l4898] [PMID: 31462531]
[36]
McGuinness, L.A.; Higgins, J.P.T. Risk‐of‐bias visualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments. Res. Synth. Methods, 2021, 12(1), 55-61.
[http://dx.doi.org/10.1002/jrsm.1411] [PMID: 32336025]
[37]
Chapter 10: Analysing data and undertaking meta-analyses. In: Deeks, J.J.H.J.; Altman, D.G., Eds.; Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A., Eds.;Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated February 2021); Cochrane, 2019.
[38]
Society, C.D. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin. J. Diabetes Mellitus, 2021, 13(04), 315-409.
[39]
Association, A.D. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care, 2021, 44(S1), S73-S84.
[http://dx.doi.org/10.2337/dc21-S006] [PMID: 33298417]
[40]
Guyatt, G.H.; Oxman, A.D.; Schünemann, H.J.; Tugwell, P.; Knottnerus, A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J. Clin. Epidemiol., 2011, 64(4), 380-382.
[http://dx.doi.org/10.1016/j.jclinepi.2010.09.011] [PMID: 21185693]
[41]
Zhang, Y.C.; Lu, B.J.; Zhao, M.H.; Rong, Y.Z.; Chen, R.M. Effect of Shengmai injection on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus. Chin. J. Integr. Med., 2008, 14(4), 281-285.
[http://dx.doi.org/10.1007/s11655-008-0281-3] [PMID: 19082800]
[42]
Lin, Z. Clinical observation of Kaishi and Shengmai injection in the treatment of Diabetic Nephropathy. J. Taish. Med. College., 2007, 28(8), 660-661.
[43]
liping W. Observation on Therapeutic effect of combination of traditional Chinese and Western Medicine on Diabetes with deficiency of both Qi and Yin. Shanxi J. Tcm., 2017, 33(1), 22-23.
[44]
Ming, C.; Haiming, W.; Hua, W. Clinical observation on shengmai injection in the treatment of diabetes of Qi and Yin Deficiency. CJGMCM, 2016, 31(18), 2618-2620.
[45]
Xiaohui, W. Clinical observation of Shengmai injection combined with alprostadil injection on diabetes peripheral neuropathy. J. Liaoning Uni. Tcm., 2009, 11(4), 115-116.
[46]
Xiaoqiu, W. Intervention in type 2 diabetes Qi Deficiency clinical studies based on the the Metabolomics Shengmai injection; Guangzhou University of Chinese Medicine, 2013.
[47]
Yegui, H. Observation on hypoglycemic effect of Shengmai injection on type 2 diabetes mellitus with deficiency of both qi and yin. J. Tradit. Chin. Med., 2006, 18(3), 257.
[48]
Yueyun, R. Clinical observation on treatment of Diabetic Nephropathy with Shengmai injection. Chinese J. Nephrop. Integr. Tradit. Chinese. West. Med., 2002, 3(12), 725-6.
[49]
Feifei, D.; Ni, W.; Ming, Q.; Yue, M. Clinical effect of Shengmai injection combined with α-lipoic acid in the treatment of diabetic patients with peripheral neuropathy. J. Navy Med., 2019, 40(04), 363-365.
[50]
Hongsheng, Z.; Suhong, S. Clinical observation of shengmai injection combined methylcobalamin on diabetic peripheral neuropathy. Gansu J. TCM., 2011, 24(04), 21-22.
[51]
Jian, Y. Observation on the efficacy of Shengmai injection in the treatment of diabetic peripheral neuropathy. J.Guilin Med. College., 1997, (03), 73.
[52]
Mingjie, Y.; Caiqiu, S. Clinical observation of Shengmai injection on urinary protein in elderly patients with Diabetic nephropathy. Chinese Health Care., 2006, 14(18), 47.
[53]
Shunyuan, D.; Ming, Y.; Junfa, X.; Hanmao, J. Effect of Shengmai injection on blood tumor necrosis factor-α and interleukin-6 in patients with type 2 diabetic nephropathy. Zhongguo Linchuang Kangfu, 2005, (3), 172-174.
[54]
Wuhai, C.; Wenjun, T.; Bin, Y. Effect of tianjiu therapy on immune function of patients with primary smear-positive pulmonary tuberculosis. Henan Trad. Chinese Med., 2011, 31(11), 1255-1257.
[55]
Xiaoqiu, W.; Zhilong, L.; Huang, Z.; Ping, D.; Yuyun, L.; Jinhua, X. The effect of early intensive insulin therapy combined with Shengmai injection on vascular inflammation factor of type 2 diabetes. J. Changchun Uni. Tradit. Chinese Med., 2014, 30(02), 295-297.
[56]
Huang, X.; Liu, G.; Guo, J.; Su, Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci., 2018, 14(11), 1483-1496.
[http://dx.doi.org/10.7150/ijbs.27173] [PMID: 30263000]
[57]
Xinkui, L.; Jiarui, W.; Dan, Z.; Xiaomeng, Z. Mechanism of shengmaisan based on network pharmacology. Zhongguo Shiyan Fangjixue Zazhi, 2017, 23(16), 219-226.
[58]
Bodan, Z.; Baohong, L.; Xiaowei, X.; Zhi, C.; Mengzhu, J.; Dudu, W. Improving effect and its mechanism of Shengmai San on insulin-resistant HepG2 cells. J. Guangdong Med. Uni., 2018, 36(03), 233-236.
[59]
Xiaohui, W.; Fei, L.; Zhongxin, D. Effect of Shengmai power on VEGF expression of pancreatic β cells in type 2 diabetic rats. Shandong Yiyao, 2018, 58(48), 45-48.
[60]
Xiaohui, W.; Fei, L.; Zhongxin, D. The effect of Shengmaisan on insulin resistance and inflammation factor in rat with type 2 diabetes. Chin J Arterioscler., 2018, 26(09), 895-899.
[61]
Xiaowei, X.; Zhi, C.; Bodan, Z.; Baohong, L.; Meiyi, X.; Dudu, W. Improvement effects of shengmai decoction on insulin resistance in diabetic rats. SHJTCM, 2018, 52(07), 80-84.
[62]
Xiaowei, X.; Zhi, C.; Xiaoliu, L.; Bodan, Z.; Baohong, L.; Wenjie, L. Shengmai powder improves insulin resistance in HepG2 cells via upregulation of β-hydroxysteroid dehydrogenase type 1 11. J. Guangdong Med. Uni., 2018, 36(05), 479-483.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy